Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Marder, S. R. Articles by Blair, K. E. Search for Related Content PubMed Citation Articles by Marder, S. R. Articles by Blair, K. E. Atypical Neuroleptics Conventional Neuroleptics Schizophrenia Spectrum Disorders

Maintenance Treatment of Schizophrenia With Risperidone or Haloperidol: 2-Year Outcomes

OBJECTIVE: Most controlled studies comparing second-generation and conventional antipsychotics have focused on the acute treatment of schizophrenia. The authors compared symptom outcomes, side effects, and social adjustment in stable schizophrenia outpatients who received 2 years of maintenance treatment with risperidone or haloperidol. METHOD: This was a 2-year, randomized, double-blind comparison of 6 mg of risperidone versus haloperidol in 63 patients with stabilized DSM-IV schizophrenia. Study patients also received 15 months of standard behavioral skills training or enhanced training with a case manager who promoted patients’ use of their skills in the community. RESULTS: The risk of psychotic exacerbations and the risk of leaving the study were similar for both drug treatment groups. However, patients who received both risperidone and the enhanced community-based skills training were more likely to remain in the study than those in the other treatment groups. Patients demonstrated significant improvement in score on the Brief Psychiatric Rating Scale over time with both medications. There were no between-group differences in cluster scores for thought disturbance, hostile-suspiciousness, and withdrawal-retardation. A significant between-group difference favoring risperidone was found for the anxious-depression cluster. Risperidone resulted in significantly greater reductions in tremor and akathisia and greater improvements in most items on the SCL-90-R. CONCLUSIONS: When compared with patients given a low dose of haloperidol, risperidone-treated patients experienced similar improvements in positive and negative symptoms and similar risks of psychotic exacerbations. However, risperidone-treated patients appeared to feel subjectively better, as indicated by less anxiety and depression and fewer extrapyramidal side effects.

This article has been cited by other articles:

				R. S. Kern, S. M. Glynn, W. P. Horan, and S. R. Marder Psychosocial Treatments to Promote Functional Recovery in Schizophrenia Schizophr Bull, March 1, 2009; 35(2): 347 - 361. [Abstract] [Full Text] [PDF]

				I. M. Bratti, J. M. Kane, and S. R. Marder Chronic Restlessness With Antipsychotics Am J Psychiatry, November 1, 2007; 164(11): 1648 - 1654. [Full Text] [PDF]

				Other articles noted Evid. Based Ment. Health, February 1, 2004; 7(1): 3 - 4. [Full Text] [PDF]

				J. Rosack Psychiatr News, September 5, 2003; 38(17): 22 - 22. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 2003 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us